Global Generic Drugs Market Size, Manufacturers, Growth Analysis Industry Forecast to 2030
Summary
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
According to APO Research, The global Generic Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Generic Drugs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Generic Drugs, also provides the value of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Generic Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Generic Drugs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Generic Drugs segment by Company
1. To analyze and research the global Generic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Generic Drugs key companies, revenue, market share, and recent developments.
3. To split the Generic Drugs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Generic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Generic Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Generic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Drugs industry.
Chapter 3: Detailed analysis of Generic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Generic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Generic Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, route of administration, quality, performance, and intended use. The term may also refer to any drug marketed under its chemical name without advertising, or to the chemical makeup of a drug rather than the brand name under which the drug is sold.
According to APO Research, The global Generic Drugs market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
North American market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Asia-Pacific market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The China market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
Europe market for Generic Drugs is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.
The major global companies of Generic Drugs include Teva, Novartis - Sandoz, Mylan, Sun Pharmaceutical, Aspen, Fresenius Kabi, Pfizer (Hospira), Sanofi and Aurobindo, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Generic Drugs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Generic Drugs, also provides the value of main regions and countries. Of the upcoming market potential for Generic Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Generic Drugs revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Generic Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Generic Drugs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Generic Drugs segment by Company
- Teva
- Novartis - Sandoz
- Mylan
- Sun Pharmaceutical
- Aspen
- Fresenius Kabi
- Pfizer (Hospira)
- Sanofi
- Aurobindo
- Lupin
- Dr. Reddy's
- Apotex
- Cipla
- ENDO (Par Pharmaceutical)
- Stada Arzneimittel
- Krka Group
- Nichi-Iko Pharmaceutical
- Valeant
- Zydus Cadila
- Hikma
- Pharmaniaga Berhad
- Hovid Berhad
- Duopharma Biotech
- Kotra Pharma
- HOE Pharmaceutical
- Y.S.P. Industries
- Prescription
- Non-Prescription Drugs
- Hospital
- Clinic
- Others
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
1. To analyze and research the global Generic Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Generic Drugs key companies, revenue, market share, and recent developments.
3. To split the Generic Drugs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Generic Drugs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Generic Drugs significant trends, drivers, influence factors in global and regions.
6. To analyze Generic Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Generic Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Generic Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Generic Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Generic Drugs industry.
Chapter 3: Detailed analysis of Generic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Generic Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Generic Drugs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
1 MARKET OVERVIEW
1.1 Product Definition
1.2 Global Generic Drugs Market Size, 2019 VS 2023 VS 2030
1.3 Global Generic Drugs Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 GENERIC DRUGS MARKET DYNAMICS
2.1 Generic Drugs Industry Trends
2.2 Generic Drugs Industry Drivers
2.3 Generic Drugs Industry Opportunities and Challenges
2.4 Generic Drugs Industry Restraints
3 GENERIC DRUGS MARKET BY COMPANY
3.1 Global Generic Drugs Company Revenue Ranking in 2023
3.2 Global Generic Drugs Revenue by Company (2019-2024)
3.3 Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Generic Drugs Company Manufacturing Base & Headquarters
3.5 Global Generic Drugs Company, Product Type & Application
3.6 Global Generic Drugs Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Generic Drugs Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Generic Drugs Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 GENERIC DRUGS MARKET BY TYPE
4.1 Generic Drugs Type Introduction
4.1.1 Prescription
4.1.2 Non-Prescription Drugs
4.2 Global Generic Drugs Sales Value by Type
4.2.1 Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Generic Drugs Sales Value by Type (2019-2030)
4.2.3 Global Generic Drugs Sales Value Share by Type (2019-2030)
5 GENERIC DRUGS MARKET BY APPLICATION
5.1 Generic Drugs Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Generic Drugs Sales Value by Application
5.2.1 Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Generic Drugs Sales Value by Application (2019-2030)
5.2.3 Global Generic Drugs Sales Value Share by Application (2019-2030)
6 GENERIC DRUGS MARKET BY REGION
6.1 Global Generic Drugs Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Generic Drugs Sales Value by Region (2019-2030)
6.2.1 Global Generic Drugs Sales Value by Region: 2019-2024
6.2.2 Global Generic Drugs Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Generic Drugs Sales Value (2019-2030)
6.3.2 North America Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Generic Drugs Sales Value (2019-2030)
6.4.2 Europe Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Generic Drugs Sales Value (2019-2030)
6.5.2 Asia-Pacific Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Generic Drugs Sales Value (2019-2030)
6.6.2 Latin America Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Generic Drugs Sales Value (2019-2030)
6.7.2 Middle East & Africa Generic Drugs Sales Value Share by Country, 2023 VS 2030
7 GENERIC DRUGS MARKET BY COUNTRY
7.1 Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Generic Drugs Sales Value by Country (2019-2030)
7.2.1 Global Generic Drugs Sales Value by Country (2019-2024)
7.2.2 Global Generic Drugs Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.3.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.4.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.5.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.6.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.7.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.8.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.9.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.10.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.11.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.12.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.13.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.14.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.15.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.16.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.17.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.18.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.19.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.20.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.21.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Teva
8.1.1 Teva Comapny Information
8.1.2 Teva Business Overview
8.1.3 Teva Generic Drugs Revenue and Gross Margin (2019-2024)
8.1.4 Teva Generic Drugs Product Portfolio
8.1.5 Teva Recent Developments
8.2 Novartis - Sandoz
8.2.1 Novartis - Sandoz Comapny Information
8.2.2 Novartis - Sandoz Business Overview
8.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2019-2024)
8.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
8.2.5 Novartis - Sandoz Recent Developments
8.3 Mylan
8.3.1 Mylan Comapny Information
8.3.2 Mylan Business Overview
8.3.3 Mylan Generic Drugs Revenue and Gross Margin (2019-2024)
8.3.4 Mylan Generic Drugs Product Portfolio
8.3.5 Mylan Recent Developments
8.4 Sun Pharmaceutical
8.4.1 Sun Pharmaceutical Comapny Information
8.4.2 Sun Pharmaceutical Business Overview
8.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
8.4.5 Sun Pharmaceutical Recent Developments
8.5 Aspen
8.5.1 Aspen Comapny Information
8.5.2 Aspen Business Overview
8.5.3 Aspen Generic Drugs Revenue and Gross Margin (2019-2024)
8.5.4 Aspen Generic Drugs Product Portfolio
8.5.5 Aspen Recent Developments
8.6 Fresenius Kabi
8.6.1 Fresenius Kabi Comapny Information
8.6.2 Fresenius Kabi Business Overview
8.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2019-2024)
8.6.4 Fresenius Kabi Generic Drugs Product Portfolio
8.6.5 Fresenius Kabi Recent Developments
8.7 Pfizer (Hospira)
8.7.1 Pfizer (Hospira) Comapny Information
8.7.2 Pfizer (Hospira) Business Overview
8.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2019-2024)
8.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
8.7.5 Pfizer (Hospira) Recent Developments
8.8 Sanofi
8.8.1 Sanofi Comapny Information
8.8.2 Sanofi Business Overview
8.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2019-2024)
8.8.4 Sanofi Generic Drugs Product Portfolio
8.8.5 Sanofi Recent Developments
8.9 Aurobindo
8.9.1 Aurobindo Comapny Information
8.9.2 Aurobindo Business Overview
8.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2019-2024)
8.9.4 Aurobindo Generic Drugs Product Portfolio
8.9.5 Aurobindo Recent Developments
8.10 Lupin
8.10.1 Lupin Comapny Information
8.10.2 Lupin Business Overview
8.10.3 Lupin Generic Drugs Revenue and Gross Margin (2019-2024)
8.10.4 Lupin Generic Drugs Product Portfolio
8.10.5 Lupin Recent Developments
8.11 Dr. Reddy's
8.11.1 Dr. Reddy's Comapny Information
8.11.2 Dr. Reddy's Business Overview
8.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2019-2024)
8.11.4 Dr. Reddy's Generic Drugs Product Portfolio
8.11.5 Dr. Reddy's Recent Developments
8.12 Apotex
8.12.1 Apotex Comapny Information
8.12.2 Apotex Business Overview
8.12.3 Apotex Generic Drugs Revenue and Gross Margin (2019-2024)
8.12.4 Apotex Generic Drugs Product Portfolio
8.12.5 Apotex Recent Developments
8.13 Cipla
8.13.1 Cipla Comapny Information
8.13.2 Cipla Business Overview
8.13.3 Cipla Generic Drugs Revenue and Gross Margin (2019-2024)
8.13.4 Cipla Generic Drugs Product Portfolio
8.13.5 Cipla Recent Developments
8.14 ENDO (Par Pharmaceutical)
8.14.1 ENDO (Par Pharmaceutical) Comapny Information
8.14.2 ENDO (Par Pharmaceutical) Business Overview
8.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2019-2024)
8.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
8.14.5 ENDO (Par Pharmaceutical) Recent Developments
8.15 Stada Arzneimittel
8.15.1 Stada Arzneimittel Comapny Information
8.15.2 Stada Arzneimittel Business Overview
8.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2019-2024)
8.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
8.15.5 Stada Arzneimittel Recent Developments
8.16 Krka Group
8.16.1 Krka Group Comapny Information
8.16.2 Krka Group Business Overview
8.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2019-2024)
8.16.4 Krka Group Generic Drugs Product Portfolio
8.16.5 Krka Group Recent Developments
8.17 Nichi-Iko Pharmaceutical
8.17.1 Nichi-Iko Pharmaceutical Comapny Information
8.17.2 Nichi-Iko Pharmaceutical Business Overview
8.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
8.17.5 Nichi-Iko Pharmaceutical Recent Developments
8.18 Valeant
8.18.1 Valeant Comapny Information
8.18.2 Valeant Business Overview
8.18.3 Valeant Generic Drugs Revenue and Gross Margin (2019-2024)
8.18.4 Valeant Generic Drugs Product Portfolio
8.18.5 Valeant Recent Developments
8.19 Zydus Cadila
8.19.1 Zydus Cadila Comapny Information
8.19.2 Zydus Cadila Business Overview
8.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2019-2024)
8.19.4 Zydus Cadila Generic Drugs Product Portfolio
8.19.5 Zydus Cadila Recent Developments
8.20 Hikma
8.20.1 Hikma Comapny Information
8.20.2 Hikma Business Overview
8.20.3 Hikma Generic Drugs Revenue and Gross Margin (2019-2024)
8.20.4 Hikma Generic Drugs Product Portfolio
8.20.5 Hikma Recent Developments
8.21 Pharmaniaga Berhad
8.21.1 Pharmaniaga Berhad Comapny Information
8.21.2 Pharmaniaga Berhad Business Overview
8.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
8.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
8.21.5 Pharmaniaga Berhad Recent Developments
8.22 Hovid Berhad
8.22.1 Hovid Berhad Comapny Information
8.22.2 Hovid Berhad Business Overview
8.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
8.22.4 Hovid Berhad Generic Drugs Product Portfolio
8.22.5 Hovid Berhad Recent Developments
8.23 Duopharma Biotech
8.23.1 Duopharma Biotech Comapny Information
8.23.2 Duopharma Biotech Business Overview
8.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2019-2024)
8.23.4 Duopharma Biotech Generic Drugs Product Portfolio
8.23.5 Duopharma Biotech Recent Developments
8.24 Kotra Pharma
8.24.1 Kotra Pharma Comapny Information
8.24.2 Kotra Pharma Business Overview
8.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2019-2024)
8.24.4 Kotra Pharma Generic Drugs Product Portfolio
8.24.5 Kotra Pharma Recent Developments
8.25 HOE Pharmaceutical
8.25.1 HOE Pharmaceutical Comapny Information
8.25.2 HOE Pharmaceutical Business Overview
8.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
8.25.5 HOE Pharmaceutical Recent Developments
8.26 Y.S.P. Industries
8.26.1 Y.S.P. Industries Comapny Information
8.26.2 Y.S.P. Industries Business Overview
8.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2019-2024)
8.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
8.26.5 Y.S.P. Industries Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
1.1 Product Definition
1.2 Global Generic Drugs Market Size, 2019 VS 2023 VS 2030
1.3 Global Generic Drugs Market Size (2019-2030)
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 GENERIC DRUGS MARKET DYNAMICS
2.1 Generic Drugs Industry Trends
2.2 Generic Drugs Industry Drivers
2.3 Generic Drugs Industry Opportunities and Challenges
2.4 Generic Drugs Industry Restraints
3 GENERIC DRUGS MARKET BY COMPANY
3.1 Global Generic Drugs Company Revenue Ranking in 2023
3.2 Global Generic Drugs Revenue by Company (2019-2024)
3.3 Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024
3.4 Global Generic Drugs Company Manufacturing Base & Headquarters
3.5 Global Generic Drugs Company, Product Type & Application
3.6 Global Generic Drugs Company Commercialization Time
3.7 Market Competitive Analysis
3.7.1 Global Generic Drugs Market CR5 and HHI
3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2023
3.7.3 2023 Generic Drugs Tier 1, Tier 2, and Tier
3.8 Mergers & Acquisitions, Expansion
4 GENERIC DRUGS MARKET BY TYPE
4.1 Generic Drugs Type Introduction
4.1.1 Prescription
4.1.2 Non-Prescription Drugs
4.2 Global Generic Drugs Sales Value by Type
4.2.1 Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030)
4.2.2 Global Generic Drugs Sales Value by Type (2019-2030)
4.2.3 Global Generic Drugs Sales Value Share by Type (2019-2030)
5 GENERIC DRUGS MARKET BY APPLICATION
5.1 Generic Drugs Application Introduction
5.1.1 Hospital
5.1.2 Clinic
5.1.3 Others
5.2 Global Generic Drugs Sales Value by Application
5.2.1 Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030)
5.2.2 Global Generic Drugs Sales Value by Application (2019-2030)
5.2.3 Global Generic Drugs Sales Value Share by Application (2019-2030)
6 GENERIC DRUGS MARKET BY REGION
6.1 Global Generic Drugs Sales Value by Region: 2019 VS 2023 VS 2030
6.2 Global Generic Drugs Sales Value by Region (2019-2030)
6.2.1 Global Generic Drugs Sales Value by Region: 2019-2024
6.2.2 Global Generic Drugs Sales Value by Region (2025-2030)
6.3 North America
6.3.1 North America Generic Drugs Sales Value (2019-2030)
6.3.2 North America Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.4 Europe
6.4.1 Europe Generic Drugs Sales Value (2019-2030)
6.4.2 Europe Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.5 Asia-Pacific
6.5.1 Asia-Pacific Generic Drugs Sales Value (2019-2030)
6.5.2 Asia-Pacific Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.6 Latin America
6.6.1 Latin America Generic Drugs Sales Value (2019-2030)
6.6.2 Latin America Generic Drugs Sales Value Share by Country, 2023 VS 2030
6.7 Middle East & Africa
6.7.1 Middle East & Africa Generic Drugs Sales Value (2019-2030)
6.7.2 Middle East & Africa Generic Drugs Sales Value Share by Country, 2023 VS 2030
7 GENERIC DRUGS MARKET BY COUNTRY
7.1 Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030
7.2 Global Generic Drugs Sales Value by Country (2019-2030)
7.2.1 Global Generic Drugs Sales Value by Country (2019-2024)
7.2.2 Global Generic Drugs Sales Value by Country (2025-2030)
7.3 USA
7.3.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.3.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.3.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.4 Canada
7.4.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.4.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.4.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.5 Germany
7.5.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.5.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.5.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.6 France
7.6.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.6.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.6.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.7 U.K.
7.7.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.7.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.7.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.8 Italy
7.8.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.8.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.8.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.9 Netherlands
7.9.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.9.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.9.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.10 Nordic Countries
7.10.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.10.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.10.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.11 China
7.11.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.11.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.11.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.12 Japan
7.12.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.12.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.12.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.13 South Korea
7.13.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.13.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.13.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.14 Southeast Asia
7.14.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.14.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.14.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.15 India
7.15.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.15.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.15.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.16 Australia
7.16.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.16.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.16.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.17 Mexico
7.17.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.17.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.17.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.18 Brazil
7.18.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.18.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.18.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.19 Turkey
7.19.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.19.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.19.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.20 Saudi Arabia
7.20.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.20.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.20.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
7.21 UAE
7.21.1 Global Generic Drugs Sales Value Growth Rate (2019-2030)
7.21.2 Global Generic Drugs Sales Value Share by Type, 2023 VS 2030
7.21.3 Global Generic Drugs Sales Value Share by Application, 2023 VS 2030
8 COMPANY PROFILES
8.1 Teva
8.1.1 Teva Comapny Information
8.1.2 Teva Business Overview
8.1.3 Teva Generic Drugs Revenue and Gross Margin (2019-2024)
8.1.4 Teva Generic Drugs Product Portfolio
8.1.5 Teva Recent Developments
8.2 Novartis - Sandoz
8.2.1 Novartis - Sandoz Comapny Information
8.2.2 Novartis - Sandoz Business Overview
8.2.3 Novartis - Sandoz Generic Drugs Revenue and Gross Margin (2019-2024)
8.2.4 Novartis - Sandoz Generic Drugs Product Portfolio
8.2.5 Novartis - Sandoz Recent Developments
8.3 Mylan
8.3.1 Mylan Comapny Information
8.3.2 Mylan Business Overview
8.3.3 Mylan Generic Drugs Revenue and Gross Margin (2019-2024)
8.3.4 Mylan Generic Drugs Product Portfolio
8.3.5 Mylan Recent Developments
8.4 Sun Pharmaceutical
8.4.1 Sun Pharmaceutical Comapny Information
8.4.2 Sun Pharmaceutical Business Overview
8.4.3 Sun Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.4.4 Sun Pharmaceutical Generic Drugs Product Portfolio
8.4.5 Sun Pharmaceutical Recent Developments
8.5 Aspen
8.5.1 Aspen Comapny Information
8.5.2 Aspen Business Overview
8.5.3 Aspen Generic Drugs Revenue and Gross Margin (2019-2024)
8.5.4 Aspen Generic Drugs Product Portfolio
8.5.5 Aspen Recent Developments
8.6 Fresenius Kabi
8.6.1 Fresenius Kabi Comapny Information
8.6.2 Fresenius Kabi Business Overview
8.6.3 Fresenius Kabi Generic Drugs Revenue and Gross Margin (2019-2024)
8.6.4 Fresenius Kabi Generic Drugs Product Portfolio
8.6.5 Fresenius Kabi Recent Developments
8.7 Pfizer (Hospira)
8.7.1 Pfizer (Hospira) Comapny Information
8.7.2 Pfizer (Hospira) Business Overview
8.7.3 Pfizer (Hospira) Generic Drugs Revenue and Gross Margin (2019-2024)
8.7.4 Pfizer (Hospira) Generic Drugs Product Portfolio
8.7.5 Pfizer (Hospira) Recent Developments
8.8 Sanofi
8.8.1 Sanofi Comapny Information
8.8.2 Sanofi Business Overview
8.8.3 Sanofi Generic Drugs Revenue and Gross Margin (2019-2024)
8.8.4 Sanofi Generic Drugs Product Portfolio
8.8.5 Sanofi Recent Developments
8.9 Aurobindo
8.9.1 Aurobindo Comapny Information
8.9.2 Aurobindo Business Overview
8.9.3 Aurobindo Generic Drugs Revenue and Gross Margin (2019-2024)
8.9.4 Aurobindo Generic Drugs Product Portfolio
8.9.5 Aurobindo Recent Developments
8.10 Lupin
8.10.1 Lupin Comapny Information
8.10.2 Lupin Business Overview
8.10.3 Lupin Generic Drugs Revenue and Gross Margin (2019-2024)
8.10.4 Lupin Generic Drugs Product Portfolio
8.10.5 Lupin Recent Developments
8.11 Dr. Reddy's
8.11.1 Dr. Reddy's Comapny Information
8.11.2 Dr. Reddy's Business Overview
8.11.3 Dr. Reddy's Generic Drugs Revenue and Gross Margin (2019-2024)
8.11.4 Dr. Reddy's Generic Drugs Product Portfolio
8.11.5 Dr. Reddy's Recent Developments
8.12 Apotex
8.12.1 Apotex Comapny Information
8.12.2 Apotex Business Overview
8.12.3 Apotex Generic Drugs Revenue and Gross Margin (2019-2024)
8.12.4 Apotex Generic Drugs Product Portfolio
8.12.5 Apotex Recent Developments
8.13 Cipla
8.13.1 Cipla Comapny Information
8.13.2 Cipla Business Overview
8.13.3 Cipla Generic Drugs Revenue and Gross Margin (2019-2024)
8.13.4 Cipla Generic Drugs Product Portfolio
8.13.5 Cipla Recent Developments
8.14 ENDO (Par Pharmaceutical)
8.14.1 ENDO (Par Pharmaceutical) Comapny Information
8.14.2 ENDO (Par Pharmaceutical) Business Overview
8.14.3 ENDO (Par Pharmaceutical) Generic Drugs Revenue and Gross Margin (2019-2024)
8.14.4 ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
8.14.5 ENDO (Par Pharmaceutical) Recent Developments
8.15 Stada Arzneimittel
8.15.1 Stada Arzneimittel Comapny Information
8.15.2 Stada Arzneimittel Business Overview
8.15.3 Stada Arzneimittel Generic Drugs Revenue and Gross Margin (2019-2024)
8.15.4 Stada Arzneimittel Generic Drugs Product Portfolio
8.15.5 Stada Arzneimittel Recent Developments
8.16 Krka Group
8.16.1 Krka Group Comapny Information
8.16.2 Krka Group Business Overview
8.16.3 Krka Group Generic Drugs Revenue and Gross Margin (2019-2024)
8.16.4 Krka Group Generic Drugs Product Portfolio
8.16.5 Krka Group Recent Developments
8.17 Nichi-Iko Pharmaceutical
8.17.1 Nichi-Iko Pharmaceutical Comapny Information
8.17.2 Nichi-Iko Pharmaceutical Business Overview
8.17.3 Nichi-Iko Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.17.4 Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
8.17.5 Nichi-Iko Pharmaceutical Recent Developments
8.18 Valeant
8.18.1 Valeant Comapny Information
8.18.2 Valeant Business Overview
8.18.3 Valeant Generic Drugs Revenue and Gross Margin (2019-2024)
8.18.4 Valeant Generic Drugs Product Portfolio
8.18.5 Valeant Recent Developments
8.19 Zydus Cadila
8.19.1 Zydus Cadila Comapny Information
8.19.2 Zydus Cadila Business Overview
8.19.3 Zydus Cadila Generic Drugs Revenue and Gross Margin (2019-2024)
8.19.4 Zydus Cadila Generic Drugs Product Portfolio
8.19.5 Zydus Cadila Recent Developments
8.20 Hikma
8.20.1 Hikma Comapny Information
8.20.2 Hikma Business Overview
8.20.3 Hikma Generic Drugs Revenue and Gross Margin (2019-2024)
8.20.4 Hikma Generic Drugs Product Portfolio
8.20.5 Hikma Recent Developments
8.21 Pharmaniaga Berhad
8.21.1 Pharmaniaga Berhad Comapny Information
8.21.2 Pharmaniaga Berhad Business Overview
8.21.3 Pharmaniaga Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
8.21.4 Pharmaniaga Berhad Generic Drugs Product Portfolio
8.21.5 Pharmaniaga Berhad Recent Developments
8.22 Hovid Berhad
8.22.1 Hovid Berhad Comapny Information
8.22.2 Hovid Berhad Business Overview
8.22.3 Hovid Berhad Generic Drugs Revenue and Gross Margin (2019-2024)
8.22.4 Hovid Berhad Generic Drugs Product Portfolio
8.22.5 Hovid Berhad Recent Developments
8.23 Duopharma Biotech
8.23.1 Duopharma Biotech Comapny Information
8.23.2 Duopharma Biotech Business Overview
8.23.3 Duopharma Biotech Generic Drugs Revenue and Gross Margin (2019-2024)
8.23.4 Duopharma Biotech Generic Drugs Product Portfolio
8.23.5 Duopharma Biotech Recent Developments
8.24 Kotra Pharma
8.24.1 Kotra Pharma Comapny Information
8.24.2 Kotra Pharma Business Overview
8.24.3 Kotra Pharma Generic Drugs Revenue and Gross Margin (2019-2024)
8.24.4 Kotra Pharma Generic Drugs Product Portfolio
8.24.5 Kotra Pharma Recent Developments
8.25 HOE Pharmaceutical
8.25.1 HOE Pharmaceutical Comapny Information
8.25.2 HOE Pharmaceutical Business Overview
8.25.3 HOE Pharmaceutical Generic Drugs Revenue and Gross Margin (2019-2024)
8.25.4 HOE Pharmaceutical Generic Drugs Product Portfolio
8.25.5 HOE Pharmaceutical Recent Developments
8.26 Y.S.P. Industries
8.26.1 Y.S.P. Industries Comapny Information
8.26.2 Y.S.P. Industries Business Overview
8.26.3 Y.S.P. Industries Generic Drugs Revenue and Gross Margin (2019-2024)
8.26.4 Y.S.P. Industries Generic Drugs Product Portfolio
8.26.5 Y.S.P. Industries Recent Developments
9 CONCLUDING INSIGHTS
10 APPENDIX
10.1 Reasons for Doing This Study
10.2 Research Methodology
10.3 Research Process
10.4 Authors List of This Report
10.5 Data Source
10.5.1 Secondary Sources
10.5.2 Primary Sources
LIST OF TABLES
Table 1. Generic Drugs Industry Trends
Table 2. Generic Drugs Industry Drivers
Table 3. Generic Drugs Industry Opportunities and Challenges
Table 4. Generic Drugs Industry Restraints
Table 5. Global Generic Drugs Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Generic Drugs Revenue Share by Company (2019-2024)
Table 7. Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Generic Drugs Key Company Manufacturing Base & Headquarters
Table 9. Global Generic Drugs Company, Product Type & Application
Table 10. Global Generic Drugs Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Generic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Prescription
Table 15. Major Companies of Non-Prescription Drugs
Table 16. Global Generic Drugs Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Generic Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Generic Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Generic Drugs Sales Value Share by Type (2019-2024)
Table 20. Global Generic Drugs Sales Value Share by Type (2025-2030)
Table 21. Major Companies of Hospital
Table 22. Major Companies of Clinic
Table 23. Major Companies of Others
Table 24. Global Generic Drugs Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 25. Global Generic Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 26. Global Generic Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 27. Global Generic Drugs Sales Value Share by Application (2019-2024)
Table 28. Global Generic Drugs Sales Value Share by Application (2025-2030)
Table 29. Global Generic Drugs Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global Generic Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 31. Global Generic Drugs Sales Value Share by Region (2019-2024)
Table 32. Global Generic Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 33. Global Generic Drugs Sales Value Share by Region (2025-2030)
Table 34. Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Generic Drugs Sales Value by Country (2019-2024) & (US$ Million)
Table 36. Global Generic Drugs Sales Value Market Share by Country (2019-2024)
Table 37. Global Generic Drugs Sales Value by Country (2025-2030) & (US$ Million)
Table 38. Global Generic Drugs Sales Value Market Share by Country (2025-2030)
Table 39. Teva Company Information
Table 40. Teva Business Overview
Table 41. Teva Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 42. Teva Generic Drugs Product Portfolio
Table 43. Teva Recent Development
Table 44. Novartis - Sandoz Company Information
Table 45. Novartis - Sandoz Business Overview
Table 46. Novartis - Sandoz Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 47. Novartis - Sandoz Generic Drugs Product Portfolio
Table 48. Novartis - Sandoz Recent Development
Table 49. Mylan Company Information
Table 50. Mylan Business Overview
Table 51. Mylan Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 52. Mylan Generic Drugs Product Portfolio
Table 53. Mylan Recent Development
Table 54. Sun Pharmaceutical Company Information
Table 55. Sun Pharmaceutical Business Overview
Table 56. Sun Pharmaceutical Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 57. Sun Pharmaceutical Generic Drugs Product Portfolio
Table 58. Sun Pharmaceutical Recent Development
Table 59. Aspen Company Information
Table 60. Aspen Business Overview
Table 61. Aspen Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 62. Aspen Generic Drugs Product Portfolio
Table 63. Aspen Recent Development
Table 64. Fresenius Kabi Company Information
Table 65. Fresenius Kabi Business Overview
Table 66. Fresenius Kabi Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 67. Fresenius Kabi Generic Drugs Product Portfolio
Table 68. Fresenius Kabi Recent Development
Table 69. Pfizer (Hospira) Company Information
Table 70. Pfizer (Hospira) Business Overview
Table 71. Pfizer (Hospira) Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 72. Pfizer (Hospira) Generic Drugs Product Portfolio
Table 73. Pfizer (Hospira) Recent Development
Table 74. Sanofi Company Information
Table 75. Sanofi Business Overview
Table 76. Sanofi Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 77. Sanofi Generic Drugs Product Portfolio
Table 78. Sanofi Recent Development
Table 79. Aurobindo Company Information
Table 80. Aurobindo Business Overview
Table 81. Aurobindo Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 82. Aurobindo Generic Drugs Product Portfolio
Table 83. Aurobindo Recent Development
Table 84. Lupin Company Information
Table 85. Lupin Business Overview
Table 86. Lupin Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 87. Lupin Generic Drugs Product Portfolio
Table 88. Lupin Recent Development
Table 89. Dr. Reddy's Company Information
Table 90. Dr. Reddy's Business Overview
Table 91. Dr. Reddy's Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Dr. Reddy's Generic Drugs Product Portfolio
Table 93. Dr. Reddy's Recent Development
Table 94. Apotex Company Information
Table 95. Apotex Business Overview
Table 96. Apotex Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Apotex Generic Drugs Product Portfolio
Table 98. Apotex Recent Development
Table 99. Cipla Company Information
Table 100. Cipla Business Overview
Table 101. Cipla Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Cipla Generic Drugs Product Portfolio
Table 103. Cipla Recent Development
Table 104. ENDO (Par Pharmaceutical) Company Information
Table 105. ENDO (Par Pharmaceutical) Business Overview
Table 106. ENDO (Par Pharmaceutical) Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
Table 108. ENDO (Par Pharmaceutical) Recent Development
Table 109. Stada Arzneimittel Company Information
Table 110. Stada Arzneimittel Business Overview
Table 111. Stada Arzneimittel Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Stada Arzneimittel Generic Drugs Product Portfolio
Table 113. Stada Arzneimittel Recent Development
Table 114. Krka Group Company Information
Table 115. Krka Group Business Overview
Table 116. Krka Group Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. Krka Group Generic Drugs Product Portfolio
Table 118. Krka Group Recent Development
Table 119. Nichi-Iko Pharmaceutical Company Information
Table 120. Nichi-Iko Pharmaceutical Business Overview
Table 121. Nichi-Iko Pharmaceutical Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
Table 123. Nichi-Iko Pharmaceutical Recent Development
Table 124. Valeant Company Information
Table 125. Valeant Business Overview
Table 126. Valeant Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Valeant Generic Drugs Product Portfolio
Table 128. Valeant Recent Development
Table 129. Zydus Cadila Company Information
Table 130. Zydus Cadila Business Overview
Table 131. Zydus Cadila Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Zydus Cadila Generic Drugs Product Portfolio
Table 133. Zydus Cadila Recent Development
Table 134. Hikma Company Information
Table 135. Hikma Business Overview
Table 136. Hikma Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 137. Hikma Generic Drugs Product Portfolio
Table 138. Hikma Recent Development
Table 139. Pharmaniaga Berhad Company Information
Table 140. Pharmaniaga Berhad Business Overview
Table 141. Pharmaniaga Berhad Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 142. Pharmaniaga Berhad Generic Drugs Product Portfolio
Table 143. Pharmaniaga Berhad Recent Development
Table 144. Hovid Berhad Company Information
Table 145. Hovid Berhad Business Overview
Table 146. Hovid Berhad Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 147. Hovid Berhad Generic Drugs Product Portfolio
Table 148. Hovid Berhad Recent Development
Table 149. Duopharma Biotech Company Information
Table 150. Duopharma Biotech Business Overview
Table 151. Duopharma Biotech Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 152. Duopharma Biotech Generic Drugs Product Portfolio
Table 153. Duopharma Biotech Recent Development
Table 154. Kotra Pharma Company Information
Table 155. Kotra Pharma Business Overview
Table 156. Kotra Pharma Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 157. Kotra Pharma Generic Drugs Product Portfolio
Table 158. Kotra Pharma Recent Development
Table 159. HOE Pharmaceutical Company Information
Table 160. HOE Pharmaceutical Business Overview
Table 161. HOE Pharmaceutical Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 162. HOE Pharmaceutical Generic Drugs Product Portfolio
Table 163. HOE Pharmaceutical Recent Development
Table 164. Y.S.P. Industries Company Information
Table 165. Y.S.P. Industries Business Overview
Table 166. Y.S.P. Industries Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 167. Y.S.P. Industries Generic Drugs Product Portfolio
Table 168. Y.S.P. Industries Recent Development
Table 169. Research Programs/Design for This Report
Table 170. Authors List of This Report
Table 171. Secondary Sources
Table 172. Primary Sources
Table 1. Generic Drugs Industry Trends
Table 2. Generic Drugs Industry Drivers
Table 3. Generic Drugs Industry Opportunities and Challenges
Table 4. Generic Drugs Industry Restraints
Table 5. Global Generic Drugs Revenue by Company (US$ Million) & (2019-2024)
Table 6. Global Generic Drugs Revenue Share by Company (2019-2024)
Table 7. Global Generic Drugs Company Ranking, 2022 VS 2023 VS 2024 & (US$ Million)
Table 8. Global Generic Drugs Key Company Manufacturing Base & Headquarters
Table 9. Global Generic Drugs Company, Product Type & Application
Table 10. Global Generic Drugs Company Commercialization Time
Table 11. Global Company Market Concentration Ratio (CR5 and HHI)
Table 12. Global Generic Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2023)
Table 13. Mergers & Acquisitions, Expansion
Table 14. Major Companies of Prescription
Table 15. Major Companies of Non-Prescription Drugs
Table 16. Global Generic Drugs Sales Value by Type 2019 VS 2023 VS 2030 (US$ Million)
Table 17. Global Generic Drugs Sales Value by Type (2019-2024) & (US$ Million)
Table 18. Global Generic Drugs Sales Value by Type (2025-2030) & (US$ Million)
Table 19. Global Generic Drugs Sales Value Share by Type (2019-2024)
Table 20. Global Generic Drugs Sales Value Share by Type (2025-2030)
Table 21. Major Companies of Hospital
Table 22. Major Companies of Clinic
Table 23. Major Companies of Others
Table 24. Global Generic Drugs Sales Value by Application 2019 VS 2023 VS 2030 (US$ Million)
Table 25. Global Generic Drugs Sales Value by Application (2019-2024) & (US$ Million)
Table 26. Global Generic Drugs Sales Value by Application (2025-2030) & (US$ Million)
Table 27. Global Generic Drugs Sales Value Share by Application (2019-2024)
Table 28. Global Generic Drugs Sales Value Share by Application (2025-2030)
Table 29. Global Generic Drugs Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 30. Global Generic Drugs Sales Value by Region (2019-2024) & (US$ Million)
Table 31. Global Generic Drugs Sales Value Share by Region (2019-2024)
Table 32. Global Generic Drugs Sales Value by Region (2025-2030) & (US$ Million)
Table 33. Global Generic Drugs Sales Value Share by Region (2025-2030)
Table 34. Global Generic Drugs Sales Value by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 35. Global Generic Drugs Sales Value by Country (2019-2024) & (US$ Million)
Table 36. Global Generic Drugs Sales Value Market Share by Country (2019-2024)
Table 37. Global Generic Drugs Sales Value by Country (2025-2030) & (US$ Million)
Table 38. Global Generic Drugs Sales Value Market Share by Country (2025-2030)
Table 39. Teva Company Information
Table 40. Teva Business Overview
Table 41. Teva Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 42. Teva Generic Drugs Product Portfolio
Table 43. Teva Recent Development
Table 44. Novartis - Sandoz Company Information
Table 45. Novartis - Sandoz Business Overview
Table 46. Novartis - Sandoz Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 47. Novartis - Sandoz Generic Drugs Product Portfolio
Table 48. Novartis - Sandoz Recent Development
Table 49. Mylan Company Information
Table 50. Mylan Business Overview
Table 51. Mylan Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 52. Mylan Generic Drugs Product Portfolio
Table 53. Mylan Recent Development
Table 54. Sun Pharmaceutical Company Information
Table 55. Sun Pharmaceutical Business Overview
Table 56. Sun Pharmaceutical Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 57. Sun Pharmaceutical Generic Drugs Product Portfolio
Table 58. Sun Pharmaceutical Recent Development
Table 59. Aspen Company Information
Table 60. Aspen Business Overview
Table 61. Aspen Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 62. Aspen Generic Drugs Product Portfolio
Table 63. Aspen Recent Development
Table 64. Fresenius Kabi Company Information
Table 65. Fresenius Kabi Business Overview
Table 66. Fresenius Kabi Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 67. Fresenius Kabi Generic Drugs Product Portfolio
Table 68. Fresenius Kabi Recent Development
Table 69. Pfizer (Hospira) Company Information
Table 70. Pfizer (Hospira) Business Overview
Table 71. Pfizer (Hospira) Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 72. Pfizer (Hospira) Generic Drugs Product Portfolio
Table 73. Pfizer (Hospira) Recent Development
Table 74. Sanofi Company Information
Table 75. Sanofi Business Overview
Table 76. Sanofi Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 77. Sanofi Generic Drugs Product Portfolio
Table 78. Sanofi Recent Development
Table 79. Aurobindo Company Information
Table 80. Aurobindo Business Overview
Table 81. Aurobindo Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 82. Aurobindo Generic Drugs Product Portfolio
Table 83. Aurobindo Recent Development
Table 84. Lupin Company Information
Table 85. Lupin Business Overview
Table 86. Lupin Generic Drugs Revenue (US$ Million) and Gross Margin (2019-2024)
Table 87. Lupin Generic Drugs Product Portfolio
Table 88. Lupin Recent Development
Table 89. Dr. Reddy's Company Information
Table 90. Dr. Reddy's Business Overview
Table 91. Dr. Reddy's Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 92. Dr. Reddy's Generic Drugs Product Portfolio
Table 93. Dr. Reddy's Recent Development
Table 94. Apotex Company Information
Table 95. Apotex Business Overview
Table 96. Apotex Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 97. Apotex Generic Drugs Product Portfolio
Table 98. Apotex Recent Development
Table 99. Cipla Company Information
Table 100. Cipla Business Overview
Table 101. Cipla Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 102. Cipla Generic Drugs Product Portfolio
Table 103. Cipla Recent Development
Table 104. ENDO (Par Pharmaceutical) Company Information
Table 105. ENDO (Par Pharmaceutical) Business Overview
Table 106. ENDO (Par Pharmaceutical) Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 107. ENDO (Par Pharmaceutical) Generic Drugs Product Portfolio
Table 108. ENDO (Par Pharmaceutical) Recent Development
Table 109. Stada Arzneimittel Company Information
Table 110. Stada Arzneimittel Business Overview
Table 111. Stada Arzneimittel Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 112. Stada Arzneimittel Generic Drugs Product Portfolio
Table 113. Stada Arzneimittel Recent Development
Table 114. Krka Group Company Information
Table 115. Krka Group Business Overview
Table 116. Krka Group Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 117. Krka Group Generic Drugs Product Portfolio
Table 118. Krka Group Recent Development
Table 119. Nichi-Iko Pharmaceutical Company Information
Table 120. Nichi-Iko Pharmaceutical Business Overview
Table 121. Nichi-Iko Pharmaceutical Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 122. Nichi-Iko Pharmaceutical Generic Drugs Product Portfolio
Table 123. Nichi-Iko Pharmaceutical Recent Development
Table 124. Valeant Company Information
Table 125. Valeant Business Overview
Table 126. Valeant Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 127. Valeant Generic Drugs Product Portfolio
Table 128. Valeant Recent Development
Table 129. Zydus Cadila Company Information
Table 130. Zydus Cadila Business Overview
Table 131. Zydus Cadila Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 132. Zydus Cadila Generic Drugs Product Portfolio
Table 133. Zydus Cadila Recent Development
Table 134. Hikma Company Information
Table 135. Hikma Business Overview
Table 136. Hikma Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 137. Hikma Generic Drugs Product Portfolio
Table 138. Hikma Recent Development
Table 139. Pharmaniaga Berhad Company Information
Table 140. Pharmaniaga Berhad Business Overview
Table 141. Pharmaniaga Berhad Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 142. Pharmaniaga Berhad Generic Drugs Product Portfolio
Table 143. Pharmaniaga Berhad Recent Development
Table 144. Hovid Berhad Company Information
Table 145. Hovid Berhad Business Overview
Table 146. Hovid Berhad Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 147. Hovid Berhad Generic Drugs Product Portfolio
Table 148. Hovid Berhad Recent Development
Table 149. Duopharma Biotech Company Information
Table 150. Duopharma Biotech Business Overview
Table 151. Duopharma Biotech Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 152. Duopharma Biotech Generic Drugs Product Portfolio
Table 153. Duopharma Biotech Recent Development
Table 154. Kotra Pharma Company Information
Table 155. Kotra Pharma Business Overview
Table 156. Kotra Pharma Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 157. Kotra Pharma Generic Drugs Product Portfolio
Table 158. Kotra Pharma Recent Development
Table 159. HOE Pharmaceutical Company Information
Table 160. HOE Pharmaceutical Business Overview
Table 161. HOE Pharmaceutical Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 162. HOE Pharmaceutical Generic Drugs Product Portfolio
Table 163. HOE Pharmaceutical Recent Development
Table 164. Y.S.P. Industries Company Information
Table 165. Y.S.P. Industries Business Overview
Table 166. Y.S.P. Industries Generic Drugs Sales (K MT), Value (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
Table 167. Y.S.P. Industries Generic Drugs Product Portfolio
Table 168. Y.S.P. Industries Recent Development
Table 169. Research Programs/Design for This Report
Table 170. Authors List of This Report
Table 171. Secondary Sources
Table 172. Primary Sources
LIST OF FIGURES
Figure 1. Generic Drugs Product Picture
Figure 2. Global Generic Drugs Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Generic Drugs Market Size (2019-2030) & (US$ Million)
Figure 4. Global Generic Drugs Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Prescription Picture
Figure 8. Non-Prescription Drugs Picture
Figure 9. Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 10. Global Generic Drugs Sales Value Share 2019 VS 2023 VS 2030
Figure 11. Global Generic Drugs Sales Value Share by Type (2019-2030)
Figure 12. Hospital Picture
Figure 13. Clinic Picture
Figure 14. Others Picture
Figure 15. Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Generic Drugs Sales Value Share 2019 VS 2023 VS 2030
Figure 17. Global Generic Drugs Sales Value Share by Application (2019-2030)
Figure 18. Global Generic Drugs Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 19. Global Generic Drugs Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 20. North America Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 22. Europe Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 24. Asia-Pacific Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia-Pacific Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Latin America Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. Latin America Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 30. USA Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 31. USA Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 32. USA Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 33. Canada Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 34. Canada Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 35. Canada Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 36. Germany Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 37. Germany Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 38. Germany Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 39. France Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 40. France Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 41. France Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 42. U.K. Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 43. U.K. Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 44. U.K. Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 45. Italy Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 46. Italy Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 47. Italy Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 48. Netherlands Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 49. Netherlands Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 50. Netherlands Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 51. Nordic Countries Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 52. Nordic Countries Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 53. Nordic Countries Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 54. China Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 55. China Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 56. China Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 57. Japan Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 58. Japan Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 59. Japan Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 60. South Korea Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 61. South Korea Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 62. South Korea Generic Drugs Sales Valu
Figure 1. Generic Drugs Product Picture
Figure 2. Global Generic Drugs Market Size (US$ Million), 2019 VS 2023 VS 2030
Figure 3. Global Generic Drugs Market Size (2019-2030) & (US$ Million)
Figure 4. Global Generic Drugs Company Revenue Ranking in 2023 (US$ Million)
Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2023 (US$ Million)
Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 7. Prescription Picture
Figure 8. Non-Prescription Drugs Picture
Figure 9. Global Generic Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 10. Global Generic Drugs Sales Value Share 2019 VS 2023 VS 2030
Figure 11. Global Generic Drugs Sales Value Share by Type (2019-2030)
Figure 12. Hospital Picture
Figure 13. Clinic Picture
Figure 14. Others Picture
Figure 15. Global Generic Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 16. Global Generic Drugs Sales Value Share 2019 VS 2023 VS 2030
Figure 17. Global Generic Drugs Sales Value Share by Application (2019-2030)
Figure 18. Global Generic Drugs Sales Value Comparison by Region: 2019 VS 2023 VS 2030 (US$ Million)
Figure 19. Global Generic Drugs Sales Value Share by Region: 2019 VS 2023 VS 2030
Figure 20. North America Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 21. North America Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 22. Europe Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 23. Europe Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 24. Asia-Pacific Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 25. Asia-Pacific Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 26. Latin America Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 27. Latin America Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 28. Middle East & Africa Generic Drugs Sales Value (2019-2030) & (US$ Million)
Figure 29. Middle East & Africa Generic Drugs Sales Value Share by Country (%), 2023 VS 2030
Figure 30. USA Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 31. USA Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 32. USA Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 33. Canada Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 34. Canada Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 35. Canada Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 36. Germany Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 37. Germany Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 38. Germany Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 39. France Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 40. France Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 41. France Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 42. U.K. Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 43. U.K. Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 44. U.K. Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 45. Italy Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 46. Italy Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 47. Italy Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 48. Netherlands Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 49. Netherlands Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 50. Netherlands Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 51. Nordic Countries Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 52. Nordic Countries Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 53. Nordic Countries Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 54. China Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 55. China Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 56. China Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 57. Japan Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 58. Japan Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 59. Japan Generic Drugs Sales Value Share by Application, 2023 VS 2030 & (%)
Figure 60. South Korea Generic Drugs Sales Value Growth Rate (2019-2030) & (US$ Million)
Figure 61. South Korea Generic Drugs Sales Value Share by Type, 2023 VS 2030 & (%)
Figure 62. South Korea Generic Drugs Sales Valu
